Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category

Glen, C., Adam, S., Coats, C. J. and Lang, N. N. (2023) Reply: Cardiotoxicity of BRAF/MEK inhibitors according to HFA/ICOS cardiotoxicity risk category. JACC: CardioOncology, 5(6), p. 850. (doi: 10.1016/j.jaccao.2023.10.003) (PMID:38204997) (PMCID:PMC10774785)

[img] Text
315227.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

78kB

Abstract

No abstract available.

Item Type:Articles (Letter)
Additional Information:CG and NNL are supported by an unrestricted grant from Roche Diagnostics. NNL is supported by a British Heart Foundation Centre of Research Excellence grant (RE/18/6/34217).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Coats, Dr Caroline and Lang, Professor Ninian and Adam, Sarah and Glen, Dr Claire
Authors: Glen, C., Adam, S., Coats, C. J., and Lang, N. N.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:JACC: CardioOncology
Publisher:Elsevier
ISSN:2666-0873
ISSN (Online):2666-0873
Copyright Holders:Copyright: © 2023 The Authors
First Published:First published in JACC: CardioOncology 5(6): 850
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303944BHF Centre of ExcellenceColin BerryBritish Heart Foundation (BHF)RE/18/6/34217SCMH - Cardiovascular & Metabolic Health